04:49 PM EST, 12/02/2024 (MT Newswires) -- TransMedics ( TMDX ) said Monday it named Gerardo Hernandez as chief financial officer.

Hernandez was most recently vice president finance, head of corporate financial planning and analysis at Alnylam Pharmaceuticals (ALNY), TransMedics ( TMDX ) said.

Hernandez succeeds Stephen Gordon, who will remain a non-executive employee until March 31, 2025.

Gordon will then become a non-employee senior advisor to TransMedics ( TMDX ) focusing on national transplant stakeholder engagement until March 31, 2026, the company said.

TransMedics ( TMDX ) also said it now expects full-year 2024 revenue between $428 million and $432 million, which is a 77% to 79% increase compared with its previous year revenue.

Analysts polled by Factset expect $431.9 million.